BCHE

Cholinesterase · P06276 · BCHE on Sugi Atlas →

364,545 patent compounds predicted against BCHE, 200,791 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Propyromazine (SCHEMBL26291)	0.55	16/20
Tianeptine (SCHEMBL49293)	0.65	15/20
Tacrine (SCHEMBL3270)	1.00	14/20
Physostigmine (SCHEMBL41555)	1.00	12/20
Physostigmine (SCHEMBL41556)	1.00	12/20
Rivastigmine (SCHEMBL2763)	1.00	11/20
Rivastigmine (SCHEMBL2764)	1.00	11/20
Physostigmine (SCHEMBL24044)	1.00	11/20
Physostigmine (SCHEMBL24045)	1.00	11/20
Ebastine (SCHEMBL18467)	0.74	11/20
Quilostigmine (SCHEMBL28872)	0.62	11/20
Ranitidine (SCHEMBL824)	0.56	11/20
Ranitidine (SCHEMBL825)	0.56	11/20
Ranitidine (SCHEMBL826)	0.56	11/20
Ranitidine (SCHEMBL33300)	0.54	11/20
Carebastine (SCHEMBL18538)	0.64	10/20
Ranitidine (SCHEMBL33298)	0.55	10/20
Ranitidine (SCHEMBL33299)	0.55	10/20
Bromide (SCHEMBL50943)	0.41	10/20
Bromide (SCHEMBL50527)	0.35	10/20

Clinical trials — most relevant to BCHE by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Detecting an Early Response to Donepezil With Measures of Visual Attention	PHASE4	COMPLETED
Treatment of Tardive Dyskinesia With Galantamine	PHASE4	COMPLETED
The Effect of Thai Traditional Music on Cognitive Function, Psychological Health and Quality of Sleep Among Thai Older Individuals With Dementia	PHASE3	COMPLETED
Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease	PHASE3	COMPLETED
Tacrine Effects on Cocaine Self-Administration and Pharmacokinetics	PHASE2	WITHDRAWN
Recovery Times of Half Dose Sugammadex and Neostigmine for Rocuronium-induced Neuromuscular Blockade	PHASE1/PHASE2	RECRUITING
Adjuvant Use of Neostigmine in Sepsis and Septic Shock.	PHASE2	COMPLETED
Guilingji Capsule for Mild-to-moderate Cognitive Impairment	PHASE2	UNKNOWN
CPC-201 Alzheimer's Disease Type Dementia: PET Study	PHASE2	WITHDRAWN
Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease	PHASE2	COMPLETED
BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.	PHASE2	COMPLETED
Mayo Acute Stroke Trial for Enhancing Recovery	PHASE2	COMPLETED
Donepezil Trial for Motor Recovery in Acute Stroke	PHASE1/PHASE2	WITHDRAWN
Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies	PHASE2	COMPLETED
Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior	PHASE2	COMPLETED
Bisnorcymserine in Healthy Adult Volunteers	PHASE1	COMPLETED
Efficacy of Intrathecal Clonidine Versus Neostigmine as Adjuvants to Bupivacaine on Postoperative Maternal and Fetal Outcomes After Elective Cesarean Section	PHASE1	UNKNOWN
Multiple Ascending Dose Putative Cognitive Enhancer VU319	PHASE1	WITHDRAWN
A Study of Possibility of Using Regulatory T Cells(VT301) for Treatment of Alzheimer's Disease	PHASE1	UNKNOWN
Phenserine on the Alzheimer's Treatment Horizon, Study 1	PHASE1	COMPLETED
Value of Butyrylcholinesterase as a Marker of Surgical Site Infection Following Surgery for Colorectal Diseases	nan	COMPLETED
Cholinesterase, Amylase, Lipase and Neutrophil-to-lymphocyte Ratio in Acute Pesticide Poisoning Cases	nan	UNKNOWN
Cholinergic Markers Alzheimer's Disease	nan	COMPLETED
The Effect of Physostigmine on Cognitive Functioning in the Immediate Period After Sedation for Colonoscopy	nan	UNKNOWN
Cholinesterase Activity and DeliriUm During Critical Illness Study	nan	COMPLETED
The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Alzheimer Disease and Mixed Dementia	nan	COMPLETED
A Study to Evaluate Sleep Quality in Patients With Mild to Moderate Alzheimer's Disease	nan	COMPLETED
Human Requirements for the Nutrient Choline	nan	COMPLETED
Follow-up of a Cohort of Patients With Myasthenic Syndrome and COVID-19 Infection	nan	COMPLETED
PET Study of Acetylcholine Esterase Activity in Alzheimer's Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a BCHE binder may also engage these)

Protein	Name	Similarity
P32749	—	1.000	P32749 →
O62760	—	1.000	O62760 →
P21927	—	1.000	P21927 →
O62761	—	1.000	O62761 →
Q03311	—	0.999	Q03311 →
P81908	—	0.999	P81908 →
Q9NDG8	—	0.997	Q9NDG8 →
Q27677	—	0.995	Q27677 →
P04058	—	0.994	P04058 →
Q9DDE3	—	0.993	Q9DDE3 →
P07692	—	0.992	P07692 →
Q5GRG2	—	0.992	Q5GRG2 →
CES1	Liver carboxylesterase 1	0.991	landscape →
Q8VCC2	—	0.991	Q8VCC2 →
B2D0J5	—	0.991	B2D0J5 →
Q27459	—	0.990	Q27459 →
W4VSJ0	—	0.989	W4VSJ0 →
O42275	—	0.989	O42275 →
Q64573	—	0.989	Q64573 →
Q63010	—	0.989	Q63010 →
O46421	—	0.989	O46421 →
Q63108	—	0.989	Q63108 →
P35502	—	0.988	P35502 →
P38433	—	0.988	P38433 →
P56161	—	0.988	P56161 →
Q8VCT4	—	0.988	Q8VCT4 →
P12992	—	0.987	P12992 →
Q04456	—	0.987	Q04456 →
P23953	—	0.987	P23953 →
D6WMZ8	—	0.987	D6WMZ8 →